RAS
DFTX

RPS Advisory Solutions’s Definium Therapeutics DFTX Stock Holding History

RPS Advisory Solutions’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-11,355
Closed -$215K – 115
2026
Q1 		$215K Buy
+11,355
New +$193K 0.12% 104

Other funds holding DFTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

RPS Advisory Solutions's DFTX Position: Q2 2026 in Review

RPS Advisory Solutions sold out of Definium Therapeutics (DFTX) in Q2 2026, closing a stake of 11,355 shares — an estimated $215K sold.

RPS Advisory Solutions first reported a position in DFTX in Q1 2026 and held it in 1 quarter. The position peaked at $215K in Q1 2026. 362 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

  • RPS Advisory Solutions reported no remaining Definium Therapeutics position as of Q2 2026 after selling out during the quarter.
  • RPS Advisory Solutions sold 11,355 Definium Therapeutics shares in Q2 2026, an estimated $215K.
  • RPS Advisory Solutions first reported a position in Definium Therapeutics in Q1 2026 and held it in 1 quarter.
  • RPS Advisory Solutions's Definium Therapeutics position peaked at $215K in Q1 2026.
  • 362 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on RPS Advisory Solutions's 13F filing for Q2 2026, filed 11 Aug 2026.